The tumor suppressor p53 plays a key role in malignant transformation and tumor development. However, the frequency of p53 mutations within individual types of cancer is different, suggesting the existence of other mechanisms attenuating p53 tumor suppressor activity. Changes in upstream regulators of p53 such as MDM2 amplification and overexpression, expression of viral oncoproteins, estrogen receptor signaling, or changes in p53 transcriptional target genes were previously described in wild-type p53 tumors. We identified a novel pathway responsible for attenuation of p53 activity in human cancers. We demonstrate that AGR2, which is overexpressed in a variety of human cancers and provides a poor prognosis, up-regulates DUSP10 which subsequently inhibits p38 MAPK and prevents p53 activation by phosphorylation. Analysis of human breast cancers reveals that AGR2 specifically provides a poor prognosis in ER+ breast cancers with wild-type p53 but not ER- or mutant p53 breast cancers, and analysis of independent data sets show that DUSP10 levels also have prognostic significance in this specific sub-group of patients. These data not only reveal a novel pro-oncogenic signaling pathway mediating resistance to DNA damaging agents in human tumors, but also has implications for designing alternative strategies for modulation of wild-type p53 activity in cancer therapy.

Regional Centre for Applied Molecular Oncology Masaryk Memorial Cancer Institute Zluty kopec 7 656 53 Brno Czech Republic

Zobrazit více v PubMed

Albain, K.S. , Barlow, W.E. , Shak, S. , Hortobagyi, G.N. , Livingston, R.B. , Yeh, I.T. , Ravdin, P. , Bugarini, R. , Baehner, F.L. , Davidson, N.E. , Sledge, G.W. , Winer, E.P. , Hudis, C. , Ingle, J.N. , Perez, E.A. , Pritchard, K.I. , Shepherd, L. , Gralow, J.R. , Yoshizawa, C. , Allred, D.C. , Osborne, C.K. , Hayes, D.F. , 2010. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol. 11, 55–65. PubMed PMC

Arumugam, T. , Deng, D. , Bover, L. , Wang, H. , Logsdon, C.D. , Ramachandran, V. , 2015. New blocking antibodies against novel AGR2-C4.4A pathway reduce growth and metastasis of pancreatic tumors and increase survival in Mice. Mol. Cancer Ther. 14, 941–951. PubMed PMC

Bailey, S.T. , Shin, H. , Westerling, T. , Liu, X.S. , Brown, M. , 2012. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc. Natl. Acad. Sci. U. S. A. 109, 18060–18065. PubMed PMC

Banin, S. , Moyal, L. , Shieh, S. , Taya, Y. , Anderson, C.W. , Chessa, L. , Smorodinsky, N.I. , Prives, C. , Reiss, Y. , Shiloh, Y. , Ziv, Y. , 1998. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science. 281, 1674–1677. PubMed

Blaydes, J.P. , Hupp, T.R. , 1998. DNA damage triggers DRB-resistant phosphorylation of human p53 at the CK2 site. Oncogene. 17, 1045–1052. PubMed

Bouchalova, P. , Nenutil, R. , Muller, P. , Hrstka, R. , Appleyard, M.V. , Murray, K. , Jordan, L.B. , Purdie, C.A. , Quinlan, P. , Thompson, A.M. , Vojtesek, B. , Coates, P.J. , 2014. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. J. Pathol. 233, 238–246. PubMed

Brychtova, V. , Vojtesek, B. , Hrstka, R. , 2011. Anterior gradient 2: a novel player in tumor cell biology. Cancer Lett. 304, 1–7. PubMed

Chen, J. , Marechal, V. , Levine, A.J. , 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13, 4107–4114. PubMed PMC

Chrisanthar, R. , Knappskog, S. , Lokkevik, E. , Anker, G. , Ostenstad, B. , Lundgren, S. , Risberg, T. , Mjaaland, I. , Skjonsberg, G. , Aas, T. , Schlichting, E. , Fjosne, H.E. , Nysted, A. , Lillehaug, J.R. , Lonning, P.E. , 2011. Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. PLoS One. 6, e19249 PubMed PMC

Dobes, P. , Podhorec, J. , Coufal, O. , Jureckova, A. , Petrakova, K. , Vojtesek, B. , Hrstka, R. , 2014. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol. Rep. 32, 1695–1702. PubMed

Forslund, A. , Zeng, Z. , Qin, L.X. , Rosenberg, S. , Ndubuisi, M. , Pincas, H. , Gerald, W. , Notterman, D.A. , Barany, F. , Paty, P.B. , 2008. MDM2 gene amplification is correlated to tumor progression but not to the presence of SNP309 or TP53 mutational status in primary colorectal cancers. Mol. Cancer Res. 6, 205–211. PubMed

Gyorffy, B. , Lanczky, A. , Eklund, A.C. , Denkert, C. , Budczies, J. , Li, Q. , Szallasi, Z. , 2010. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res. Treat. 123, 725–731. PubMed

Harris, S.L. , Levine, A.J. , 2005. The p53 pathway: positive and negative feedback loops. Oncogene. 24, 2899–2908. PubMed

Haupt, Y. , Maya, R. , Kazaz, A. , Oren, M. , 1997. Mdm2 promotes the rapid degradation of p53. Nature. 387, 296–299. PubMed

Hengel, S.M. , Murray, E. , Langdon, S. , Hayward, L. , O'Donoghue, J. , Panchaud, A. , Hupp, T. , Goodlett, D.R. , 2011. Data-independent proteomic screen identifies novel tamoxifen agonist that mediates drug resistance. J. Proteome Res. 10, 4567–4578. PubMed PMC

Hrstka, R. , Nenutil, R. , Fourtouna, A. , Maslon, M.M. , Naughton, C. , Langdon, S. , Murray, E. , Larionov, A. , Petrakova, K. , Muller, P. , Dixon, M.J. , Hupp, T.R. , Vojtesek, B. , 2010. The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene. 29, 4838–4847. PubMed

Hrstka, R. , Brychtova, V. , Fabian, P. , Vojtesek, B. , Svoboda, M. , 2013. AGR2 predicts tamoxifen resistance in postmenopausal breast cancer patients. Dis. Markers. 35, 207–212. PubMed PMC

Hublarova, P. , Greplova, K. , Holcakova, J. , Vojtesek, B. , Hrstka, R. , 2010. Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases. Cell. Mol. Biol. Lett. 15, 473–484. PubMed PMC

Innes, H.E. , Liu, D. , Barraclough, R. , Davies, M.P. , O'Neill, P.A. , Platt-Higgins, A. , de Silva Rudland, S. , Sibson, D.R. , Rudland, P.S. , 2006. Significance of the metastasis-inducing protein AGR2 for outcome in hormonally treated breast cancer patients. Br. J. Cancer. 94, 1057–1065. PubMed PMC

Jeffrey, K.L. , Camps, M. , Rommel, C. , Mackay, C.R. , 2007. Targeting dual-specificity phosphatases: manipulating MAP kinase signalling and immune responses. Nat. Rev. Drug Discov. 6, 391–403. PubMed

Jiang, L. , Kon, N. , Li, T. , Wang, S.J. , Su, T. , Hibshoosh, H. , Baer, R. , Gu, W. , 2015. Ferroptosis as a p53-mediated activity during tumour suppression. Nature. 520, 57–62. PubMed PMC

Kim, Y. , Kweon, J. , Kim, A. , Chon, J.K. , Yoo, J.Y. , Kim, H.J. , Kim, S. , Lee, C. , Jeong, E. , Chung, E. , Kim, D. , Lee, M.S. , Go, E.M. , Song, H.J. , Kim, H. , Cho, N. , Bang, D. , Kim, J.S. , 2013. A library of TAL effector nucleases spanning the human genome. Nat. Biotechnol. 31, 251–258. PubMed

Konduri, S.D. , Medisetty, R. , Liu, W. , Kaipparettu, B.A. , Srivastava, P. , Brauch, H. , Fritz, P. , Swetzig, W.M. , Gardner, A.E. , Khan, S.A. , Das, G.M. , 2010. Mechanisms of estrogen receptor antagonism toward p53 and its implications in breast cancer therapeutic response and stem cell regulation. Proc. Natl. Acad. Sci. U. S. A. 107, 15081–15086. PubMed PMC

Kruse, J.P. , Gu, W. , 2009. Modes of p53 regulation. Cell. 137, 609–622. PubMed PMC

Lane, D.P. , 1992. Cancer. p53, guardian of the genome. Nature. 358, 15–16. PubMed

Lee, J.T. , Gu, W. , 2010. The multiple levels of regulation by p53 ubiquitination. Cell Death Differ. 17, 86–92. PubMed PMC

Lim, Y.P. , Lim, T.T. , Chan, Y.L. , Song, A.C. , Yeo, B.H. , Vojtesek, B. , Coomber, D. , Rajagopal, G. , Lane, D. , 2007. The p53 knowledgebase: an integrated information resource for p53 research. Oncogene. 26, 1517–1521. PubMed

Liu, W. , Ip, M.M. , Podgorsak, M.B. , Das, G.M. , 2009. Disruption of estrogen receptor alpha-p53 interaction in breast tumors: a novel mechanism underlying the anti-tumor effect of radiation therapy. Breast Cancer Res. Treat. 115, 43–50. PubMed PMC

Michalova, E. , Poprach, A. , Nemeckova, I. , Nenutil, R. , Valik, D. , Zaloudik, J. , Vyzula, R. , Vojtesek, B. , 2008. Chemosensitivity prediction in tumor cells ex vivo–difficulties and limitations of the method. Klin. Onkol. 21, 93–97. PubMed

Mosmann, T. , 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 65, 55–63. PubMed

Olivier, M. , Langerod, A. , Carrieri, P. , Bergh, J. , Klaar, S. , Eyfjord, J. , Theillet, C. , Rodriguez, C. , Lidereau, R. , Bieche, I. , Varley, J. , Bignon, Y. , Uhrhammer, N. , Winqvist, R. , Jukkola-Vuorinen, A. , Niederacher, D. , Kato, S. , Ishioka, C. , Hainaut, P. , Borresen-Dale, A.L. , 2006. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin. Cancer Res. 12, 1157–1167. PubMed

Olivier, M. , Hollstein, M. , Hainaut, P. , 2010. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb. Perspect. Biol. 2, a001008 PubMed PMC

Owens, D.M. , Keyse, S.M. , 2007. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 26, 3203–3213. PubMed

Paik, S. , Tang, G. , Shak, S. , Kim, C. , Baker, J. , Kim, W. , Cronin, M. , Baehner, F.L. , Watson, D. , Bryant, J. , Costantino, J.P. , Geyer, C.E. , Wickerham, D.L. , Wolmark, N. , 2006. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3726–3734. PubMed

Petitjean, A. , Achatz, M.I. , Borresen-Dale, A.L. , Hainaut, P. , Olivier, M. , 2007. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene. 26, 2157–2165. PubMed

Pohler, E. , Craig, A.L. , Cotton, J. , Lawrie, L. , Dillon, J.F. , Ross, P. , Kernohan, N. , Hupp, T.R. , 2004. The Barrett's antigen anterior gradient-2 silences the p53 transcriptional response to DNA damage. Mol. Cell. Proteomics. 3, 534–547. PubMed

Poprach, A. , Michalova, E. , Pavlik, T. , Lakomy, R. , Vyskocil, J. , Nemeccek, R. , Zaloudik, J. , Vyzula, R. , Kocak, I. , Kocakova, I. , 2008. Actual state of ex vivo chemoresistance testing of malignant tumors in Masaryk Memorial Cancer Institute Brno. Klin. Onkol. 21, 116–121. PubMed

Ramachandran, V. , Arumugam, T. , Wang, H. , Logsdon, C.D. , 2008. Anterior gradient 2 is expressed and secreted during the development of pancreatic cancer and promotes cancer cell survival. Cancer Res. 68, 7811–7818. PubMed PMC

Regner, B. , Dusek, L. , Hajduch, M. , 2000. Software chemoresist version 1.0 – a complex tool for data analysis a management of tumor drug resistance testing. Klin. Onkol. 13, 30–32.

Salmans, M.L. , Zhao, F. , Andersen, B. , 2013. The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarker. Breast Cancer Res. 15, 204 PubMed PMC

Sato, Y. , Tsurumi, T. , 2013. Genome guardian p53 and viral infections. Rev. Med. Virol. 23, 213–220. PubMed

Sayeed, A. , Konduri, S.D. , Liu, W. , Bansal, S. , Li, F. , Das, G.M. , 2007. Estrogen receptor alpha inhibits p53-mediated transcriptional repression: implications for the regulation of apoptosis. Cancer Res. 67, 7746–7755. PubMed

Simpson, N.E. , Lambert, W.M. , Watkins, R. , Giashuddin, S. , Huang, S.J. , Oxelmark, E. , Arju, R. , Hochman, T. , Goldberg, J.D. , Schneider, R.J. , Reiz, L.F. , Soares, F.A. , Logan, S.K. , Garabedian, M.J. , 2010. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res. 70, 8446–8456. PubMed PMC

Theodosiou, A. , Smith, A. , Gillieron, C. , Arkinstall, S. , Ashworth, A. , 1999. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 18, 6981–6988. PubMed

Thompson, D.A. , Weigel, R.J. , 1998. hAG-2, the human homologue of the Xenopus laevis cement gland gene XAG-2, is coexpressed with estrogen receptor in breast cancer cell lines. Biochem. Biophys. Res. Commun. 251, 111–116. PubMed

Vojtesek, B. , Bartek, J. , Midgley, C.A. , Lane, D.P. , 1992. An immunochemical analysis of the human nuclear phosphoprotein p53. New monoclonal antibodies and epitope mapping using recombinant p53. J. Immunol. Methods. 151, 237–244. PubMed

Wade, M. , Li, Y.C. , Wahl, G.M. , 2013. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat. Rev. Cancer. 13, 83–96. PubMed PMC

Wang, Z. , Hao, Y. , Lowe, A.W. , 2008. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res. 68, 492–497. PubMed

Yamashita, H. , Toyama, T. , Nishio, M. , Ando, Y. , Hamaguchi, M. , Zhang, Z. , Kobayashi, S. , Fujii, Y. , Iwase, H. , 2006. p53 protein accumulation predicts resistance to endocrine therapy and decreased post-relapse survival in metastatic breast cancer. Breast Cancer Res. 8, R48 PubMed PMC

Yu, H. , Yue, X. , Zhao, Y. , Li, X. , Wu, L. , Zhang, C. , Liu, Z. , Lin, K. , Xu-Monette, Z.Y. , Young, K.H. , Liu, J. , Shen, Z. , Feng, Z. , Hu, W. , 2014. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat. Commun. 5, 5218 PubMed PMC

Characterization of the AGR2-NPM3 axis uncovers the AGR2 involvement in PD-L1 regulation in colorectal cancer

Anterior gradient proteins in gastrointestinal cancers: from cell biology to pathophysiology

Identification of AGR2 Gene-Specific Expression Patterns Associated with Epithelial-Mesenchymal Transition

Characterization of the AGR2 Interactome Uncovers New Players of Protein Disulfide Isomerase Network in Cancer Cells

AGR2 silencing contributes to metformin-dependent sensitization of colorectal cancer cells to chemotherapy

Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition